| Bioactivity | CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PSMA inhibitory activity (IC50=1 nM). (Pink: PSMA Inhibitor Stent (HY-139840); Black: linker (HY-W037980); Blue: PARP ligand (HY-10162))[1] |
| CAS | 3024354-59-1 |
| Formula | C40H47FN8O12 |
| Molar Mass | 850.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Q, et al. A Prostate-Specific Membrane Antigen-Targeting Small Molecule–Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib[J]. Journal of Medicinal Chemistry, 2024. |